Rare Disease Report
Patients & Caregivers


The review panel found more deaths in multiple myeloma patients getting pembrolizumab plus pomalidomide or lenalidomide vs control groups.
Menounos began to suspect she had brain cancer based on her own symptoms (trouble speaking) as well as her experience caring for her mother who currently has stage 4 brain cancer.
Alopecia, or hair loss, is a common side effect of chemotherapies often used to treat treatment solid tumor cancers.
The FDA has approved Beckman Coulter's ClearLLab Reagents to help diagnose numerous rare blood cancers, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).
The study observed that overall survival was significantly longer in the midostaurin group (74.7 months) compared to the placebo group (25.6 months; P = .009).
The new route of administration can allow patients to be treated within minutes rather than the hours currently needed to administer rituximab intravenously.
Former hemihypertrophy and Wilms' tumor patient and current nose tackle Mike Pennel arrived at camp last week for his first week on the job as a New York Jet.
There's a belief that these drugs should be withheld from elderly thyroid cancer patients due to toxicity and other medical concerns, but the results show lenvatinib is safe and effective.
Biotech company Accerelon announced it will discontinue development of dalantercept to treat RCC based on preliminary results from their DART Phase 2 study.
An increased number of deaths observed in 2 Phase 3 cancer studies involving Keytruda (pembrolizumab) in multiple myeloma patients has led Merck to pause recruitment.
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.